[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334012-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334012-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","latin-american-challenges-and-recommendations-for-poly-adenosine-diphosphate-ribose-polymerase-inhibitor-treatment-in-metastatic-castration-resistant-prostate-cancer-an-expert-overview-cancer-control-volume-31","Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview - Cancer Control Volume 31","","Latin America faces a high prostate cancer burden, with prostate cancer as the most common cancer among men and the region carrying the highest mortality rates. For metastatic castration-resistant prostate cancer, poly-ADP ribose polymerase inhibitors expand treatment options but create new challenges around surveillance and early detection of castration resistance. An expert panel convened by the Americas Health Foundation reviews evidence and recommends precision medicine pathways, including genotyping, population databases, biobanks, and multi-stakeholder collaboration to reduce access barriers and costs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/latin-american-challenges-and-recommendations-for-poly-adenosine-diphosphate-ribose-polymerase-inhibitor-treatment-in-metastatic-castration-resistant-prostate-cancer-an-expert-overview-cancer-control-volume-31/334012/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/latin-american-challenges-and-recommendations-for-poly-adenosine-diphosphate-ribose-polymerase-inhibitor-treatment-in-metastatic-castration-resistant-prostate-cancer-an-expert-overview-cancer-control-volume-31/334012.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is prostate cancer a major concern in Latin America?","Question",{"text":63,"@type":64},"Prostate cancer is the third most common cancer overall and the most common among men in Latin America, with the highest mortality rate among cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What challenges arise when using poly-ADP ribose polymerase inhibitors in mCRPC?",{"text":68,"@type":64},"Key challenges include developing monitoring protocols for early detection of disease progression to castration resistance, and overcoming limited access to genetic testing and associated infrastructure.",{"name":70,"@type":61,"acceptedAnswer":71},"What recommendations does the expert panel make to improve patient care?",{"text":72,"@type":64},"The panel recommends building population databases and biobanks, establishing tumor tissue collection/processing/storage facilities, and enabling multi-stakeholder collaboration to improve accessibility and reduce drug and counseling cost burdens.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334012,1790318681,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview  \nCancer Control Volume 31: 1–10  \n© The Author(s) 2024  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748241280446](DOI: 10.1177/10732748241280446)[ ](DOI: 10.1177/10732748241280446)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nRodolfo Borges dos Reis, MD, PHD 1 􀀁, Jos L. Aguilar-Ponce, MD2,  \nFederico Cayol, MD, MSc3, Angela M. Jansen, PhD, MHS4 􀀁, Ray Manneh K, MD, MSc5, Tomas R Merino, MD6, Gayatri Sanku, PhD, MPH4, Laura B. Vaca, MD7,  \nPedro Isaacsson Velho, MD8,9, and Ernesto P. Korbenfeld, MD 10  \nAbstract  \nIn Latin America, prostate cancer is the third most common cancer overall and the most common in men, with the highest mortality rate of all cancers. In 2022, there were approximately 22,985 new prostate cancer cases and 61,056 deaths from prostate cancer in the region. Patients with metastatic disease that is resistant to cure by castration now have multiple therapeutic options, including poly-ADP ribose polymerase inhibitors. These treatment advances present new challenges, such as developing monitoring protocols for early detection of disease progression to castration resistance. The Americas Health Foundation organized a 3-day meeting with 8 regional oncologists and pathologists to create a paper on metastatic castrationresistant prostate cancer diagnosis and therapy, including the new poly-ADP ribose polymerase inhibitors. The panel examined metastatic castration-resistant prostate cancer in Latin America and recommended ways to improve patient care using published literature and their expertise. Gene mutations play an important role in prostate cancer development. Precision medicine innovations highlight the importance of genotyping DNA variants and tumor biomarkers for targeted treatment. Access to appropriate genetic testing is difﬁcult, medications are available but expensive, and there is a lack of infrastructure and regulatory frameworks that prevent patients from beneﬁting from innovative therapies. The panel recommends developing a population database and biobank and creating tumor tissue collection, processing, and storage facilities. Multi-stakeholder collaboration is needed to integrate the information gathered, train staff, select target populations, improve patient accessibility, and reduce the cost burden of drugs, genetic counselors, and cancer geneticists in Latin America. Collaboration is essential  \n1 Department of Surgery, Ribeirão Preto Medical School, The University of São Paulo, Brazil 2Department of Medica Oncology, Instituto Nacional de CancerologiaMxico, Mexico City, Mexico 3Sección de Oncolog´ıa, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina  \n4Americas Health Foundation, Washington, DC, USA  \n5Medical Oncology Research Institute, Sociedad de Oncolog´ıa y Hematolog´ıa del Cesar, Valledupar, Cesar, Colombia 6Departamento de Hemato Oncolog´ıa, Universidad de Santiago de Chile, Santiago, Chile  \n7Clinical Oncology, Cl´ınica Universitaria Colombia, Cl´ınica de Marly Bogot, Colombia 8Oncology, Hospital Moinhos de Vento, Porto Alegre, Brazil  \n9Johns Hopkins Hospital, Baltimore, MD, USA  \n10Oncology, Hospital Britnico de Buenos Aires, Buenos Aires, Argentina  \nCorresponding Author:  \nRodolfo Borges dos Reis, Division of Urology, Department of Surgery and Anatomy, Ribeirão Preto Medical School, The University of São Paulo, Av. Bandeirantes, 3900, Ribeirao Preto-SP, 14049-900, Brazil.  \nEmail: [rodolforeis@fmrp.usp.br](rodolforeis@fmrp.usp.br)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits n","cbCaieQhvTbeJisX","https://ap.wps.com/l/cbCaieQhvTbeJisX","pdf",1178352,"English","# Abstract\n# Introduction\n## Prostate cancer burden in Latin America\n## Molecular basis of treatment resistance and HRR alterations\n## PARP inhibitors for mCRPC with HRR abnormalities\n# Keywords\n# Received and publication dates","[{\"question\":\"Why is prostate cancer a major concern in Latin America?\",\"answer\":\"Prostate cancer is the third most common cancer overall and the most common among men in Latin America, with the highest mortality rate among cancers.\"},{\"question\":\"What challenges arise when using poly-ADP ribose polymerase inhibitors in mCRPC?\",\"answer\":\"Key challenges include developing monitoring protocols for early detection of disease progression to castration resistance, and overcoming limited access to genetic testing and associated infrastructure.\"},{\"question\":\"What recommendations does the expert panel make to improve patient care?\",\"answer\":\"The panel recommends building population databases and biobanks, establishing tumor tissue collection/processing/storage facilities, and enabling multi-stakeholder collaboration to improve accessibility and reduce drug and counseling cost burdens.\"}]","Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview - Cancer Control Volume 31 | PDF",1790004991,25]